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blets (n529, 72%), particularly carboplatin-paclitaxel (n285, 39%), accounted for
most off-label GL concordant care. NCCN GL recommendations for carboplatin-
based doublets are supported by phase III clinical trials. CONCLUSIONS: The ma-
jority of advanced NSCLC patients received first-line therapy that was concordant
with NCCN GL recommendations but was outside the FDA labeled indication.
These GL concordant, off-label uses are supported by high-level evidence including
phase III clinical trials.
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OBJECTIVES: The aim of this study was to assess treatment choices for patients
diagnosed withmetastatic melanoma in SUS settings.METHODS: The patient flow
pathway was determined by patients receiving systemic therapy for diagnosed
melanoma stage IV (ICD-C43) from a government administrative database (SIA/
DATASUS). Patients ineligible for upfront therapy could not be captured. Systemic
therapy at each line treatment and time to progression data from Jan/2008 to Jun/
2010 was collected. Patients were classified as active (analyzed during all period),
lost during follow-up (unknown reason) and dead. RESULTS: Data from 1,049 pa-
tients was analyzed, 48.1% lost follow up and 8.3% had documented death. By the
end of the study, 43.6% were still active. The average follow-up time was 8.6
months. All patients received at least one line of systemic therapy. First line ther-
apy (FLT), 49.7% received dacarbazine and 29.1% interferon. By Jun/2010, 175
(16.7%) patients received second line therapy (SLT), 42.5% lost follow-up, 6.6% died
and 34.2% remained in FLT. The most common SLT regimens were dacarbazine
(28.0%), interferon (17.7%) and paclitaxel (14.9%) and the average time to switch
from FLT to SLT was 5.5 months. During SLT, 28.0% lost follow-up, 7.4% died and
47.4%of patient remained active till jun/2010. Thirty patients (2.9%) received a third
line therapy (TLT), with an average time from the beginning of SLT to TLT of 5.2
months. Paclitaxel (23.3%) and interferon (20.0%) were the most commonly used
regimens. CONCLUSIONS: For metastatic melanoma patients in the SUS, the main
chemotherapy regimens in FLT and SLT were dacarbazine and interferon. Pacli-
taxel was the most common TLT agent along with interferon.
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OBJECTIVES: The objective of this systematic review was to identify treatment
guidelines for metastatic colorectal cancer (mCRC) and to assess guideline
recommendations. METHODS: Publications were identified through electronic
searches of MEDLINE, MEDLINE In Process, EMBASE and the Cochrane Library;
through manual searches of the reference lists of relevant articles; and by search-
ing websites on the Internet. The MEDLINE and EMBASE searches were limited to
articles published in English, whereas the Cochrane library search had no language
restrictions.RESULTS:A total of 1,633 citations/abstractswere identified fromelec-
tronic database searches. Of these, 91 underwent full-paper review and 32 were
included in the final analysis. In addition, 25 articles were identified from manual
andwebsite searches, giving a total of 57 guidelines. The guidelineswere published
between 1996 and 2010, with the majority published between 2004 and 2010. The
country publishing the most guidelines was the USA (12), followed by the UK (10),
Canada (8), France (8), Germany (3), Australia (2), Spain (2) and Italy (1). In addition,
eight European and three International guidelines were identified. As monoclonal
antibody therapy for mCRC was not introduced until 2004, no firm recommenda-
tions formonoclonal antibody therapyweremade in guidelines published between
2004 and 2006. Recommendations for monoclonal antibody therapy first appeared
in 2007 and evolved asmore data became available. Themost recent international,
European, and US guidelines recommended combination chemotherapy with a
monoclonal antibody for the first-line treatment of mCRC, while second-line treat-
ment varied depending on the first-line regimen used. Cetuximab and panitu-
mumab were recommended in patients with wild-type KRAS mCRC.
CONCLUSIONS: The findings from this systematic review indicate that these re-
cent treatment guidelines have recognized the role ofmonoclonal antibodies in the
management of mCRC; and timely treatment guideline updates are necessary to
reflect the most recently available data.
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OBJECTIVES: This study aims to describe clinical and demographic characteristics
of chronic myelogenous leukemia (CML) patients receiving therapy on public can-
cer centers in São Paulo state, Brazil. METHODS: Cross-sectional analysis of São
Paulo state CML-related pharmacy claims as reported in the Ambulatory Informa-
tion System database. Patients were included if they have at least one claim with
CML ICD-10 code during April 2010. Repeated records were excluded using identi-
fication code, age, sex, and diagnosis date as compatibility criteria. Kruskal-Wallis
test was used to compare clinical and demographical variables and cost of treat-
ment among patients receiving each protocol. RESULTS: 1,326 patients were iden-
tified as CML patients, 53.32%male with a mean age of 51.08 years (SD17.07). The
mean disease duration was 2.38 years (SD3.02; range 0-21.27 years) for those
patients for whom data was available (n1,307). The proportion of patients receiv-
ing tyrosine kinase inhibitors (TKI)was 85.67% (imatinib74.06%; dasatinib8.82%;
nilotinib2.79%). Other reported therapeutic strategies were: hydroxyurea (7.24%),
non specified oral cancer therapy (3.17%), chemotherapy protocols (0.75%), inter-
feron (0.60%), and others (2.56%). Median age was significantly (p0.05) different
among hydroxyurea-treated patients (67 years), others (46 years), and chemother-
apy (15 years) as compared to TKI, interferon and non specified oral drugs. Higher
median disease duration was observed for nilotinib-treated patients (4.74 years),
interferon (2.73), and dasatinib (2.31). The median disease duration of imatinib
treated patients was 0.96 years (p0.05 vs. all comparisons except hydroxyurea).
Themedian cost of treatment ranged from 80 BRL to 6,678 BRL for hydroxyurea and
nilotinib (p0.05). CONCLUSIONS: Among this sample, the most frequent thera-
peutic approach for CML patients was TKI, particularly imatinib, but second-gen-
eration TKIs have also been prescribed for patients with significantly longer dis-
ease duration, which is consistent with current guidelines that recommend that
they should be prescribed in later lines.
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OBJECTIVES: The aim of this study is to document treatment patterns of care and
associated costs of metastatic melanoma in Brazil from the Public Health System
(SUS) Perspective. METHODS: A review of a government administrative claims
database (Outpatient Information System - SIA/DATASUS)was conducted from Jan
2008 to June 2010. Patients receiving radiotherapy and/or systemic therapy for
diagnosed melanoma (International Code of Disease (ICD-10) C43) stage IV were
included in the analysis. Information on type of treatment (chemotherapy, radio-
therapy), chemotherapy scheme, length of treatment and associated costs (in 2010
USD)were collected.RESULTS: 2,488 patientsmet the inclusion criteria, 54.3%male
with an average age (SD) of 56.3 (15.0) years. 42.2% lived in the Southeast region and
38.5% in the South. Less than 40% of the cases had the primary cancer site reported.
Dacarbazine was the most widely used agent (administered to 1,700 patients),
followed by interferon (1,059 patients) and cisplatin (435 patients). Dacarbazine
monotherapy was the most commonly administered chemotherapy regimen
(37.9% of the patients; average length of treatment of 3.1 months), followed by
interferon monotherapy (30.1% of the patients; average length of treatment of 4.6
months) and paclitaxel monotherapy (3.5% of the patients; average length of treat-
ment of 2.8 months). Overall cost of care expenses were USD16,238,160, 99% of the
cost was attributable to chemotherapy (USD16,024,555). Total expenses in 2009
(USD6,667,687) increased 12% compared to 2008; interferon monotherapy ac-
counted for 38.5% (USD6,245,742) of expenses, and dacarbazine monotherapy ac-
counted for 32.2% (USD5,230,315). CONCLUSIONS: Patients with advanced mela-
noma, in the Brazilian Public Healthcare System (SUS), nearly all receive systemic
therapy. Dacarbazine as single agent is the most common regimen, followed by
interferon with a significant financial impact to the Public Healthcare System, to-
talizing USD16,238,160 in the last two and a half years.
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OBJECTIVES: NSCLC (accounting for 80% of all cases of lung cancer) causes high
morbidity and mortality. Various treatment lines are available for NSCLC, and
there are ongoing discussions on the most appropriate measure of treatment effi-
cacy for reimbursement decisions. We examined the use of these endpoints in
NSCLC from a payers’ perspective.METHODS: Targeted searches were conducted
in MEDLINE® and the Cochrane Database of Reviews, using clinical and health
economic-related key words and limited from 2000 to 2010. RESULTS: OS can be
measured easily and accurately in terms of both event and time and is the endpoint
preferred by regulatory bodies including the FDA and EMA. Over the last 10 years
the benchmark OS for first-line treatment of NSCLC has risen and it is increasingly
difficult to demonstrate significant OS benefit, as the efficacy (clinical trial results)
of treatments has improved. Demonstrating improvements in OS over best sup-
portive care is less challenging than against an active comparator. Adequate pow-
ering of studies to demonstrate OS benefit is vital but requires large study popula-
tions. Demonstrating a significant PFS benefit is also challenging, requiring
frequent assessments, precise event definition and exact determination of the time
of event. Nevertheless, PFS provides a well-accepted alternative endpoint to OS as
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